Clinical trials: Lung Diseases, Interstitial
Idiopathic Pulmonary Fibrosis
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.
- Trial name
- QUALIFY IPF (NCT03710824)
- Testing
- Nintedanib
- Where
- 10 sites in Greece
- Volunteers
- 180 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer and Idiopathic Pulmonary Fibrosis
Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization
Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers.
- Trial name
- K-FPI (NCT03486262)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Langerhans Cell Histiocytosis
A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
Langerhans cell histiocytosis (LCH) is a disease caused by clonal expansion, proliferation, and dissemination of cells that are phenotypically close to Langerhans cells in different tissues and organs.
- Trial name
- NCT03585686
- Testing
- Vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
- Where
- Russia
- Volunteers
- 12 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Idiopathic Interstitial Pneumonias
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
We hypothesize that a peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose…
- Trial name
- NCT01151527
- Where
- 2 sites in United States
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Duke University
Idiopathic Pulmonary Fibrosis
PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort
The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical data from electronic health records (EHR) and patient reported outcomes (PRO) to answer questions of clinical importance to patients with…
- Trial name
- NCT02407431
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pittsburgh
Lung Disease
Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease
The investigators hypothesise that H2H will result in improved symptom control and quality of life and may be more cost-effective than standard best practice.
- Trial name
- H2H-ILD (NCT01450644)
- Testing
- The Hospital2Home Service
- Where
- 2 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Hospitalized Cases of Angioneurotic Oedema, Pneumonia
Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists
The purpose of this study is 1. To describe patient characteristics and drug usage among children that are prescribed esomeprazole for the first time and to compare them with patients who are prescribed other proton pump…
- Conditions
- Hospitalized Cases of Angioneurotic Oedema, Pneumonia, Gastroenteritis, Failure to Thrive
- Trial name
- NCT01338363
- Where
- Netherlands
- Volunteers
- 23,470 people
- Sponsor
- AstraZeneca
Pneumonitis, Interstitial, Immune Checkpoint Inhibitors (ICIs)
Exploratory Study on the Efficacy and Safety of Nebulized hUC-MSC-Derived Exosomes for Non-Acute CIP
Study Objectives The primary objective of Phase II is to evaluate the percentage of lesion resolution on high-resolution computed tomography (HRCT) as assessed by independent blinded reviewers.
- Conditions
- Pneumonitis, Interstitial, Immune Checkpoint Inhibitors (ICIs), Mesenchymal Stem Cells, Exosomes
- Trial name
- NCT07599111
- Testing
- Nebulized hUCMSC-Exos, Nebulized normal saline
- Volunteers
- 40 people
- Sponsor
- Zhou Chengzhi
Fibrotic Interstitial Lung Disease
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
The investigators plan to conduct a study to find out if giving portable oxygen therapy (during physical activity) to patients with interstitial lung disease will improve quality of life, exercise tolerance, shortness of breath…
- Trial name
- NCT06053164
- Testing
- Exertional Oxygen, Education and Support
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of Alberta
Systemic Lupus Erythematosus
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and…
- Trial name
- NCT06576271
- Testing
- GSK4527363, Belimumab
- Where
- 28 sites in United States, Argentina and 4 more
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Granulomatosis With Polyangiitis (Wegener's)
Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3
The goal of this observational study is to quantify activity and extent of disease in patients with GPA using 18F-FDG PET/CT. The main questions it aims to answer are: Sensitivity of 18 F-FDG PET/CT in patients with GPA?…
- Trial name
- NCT07712172
- Testing
- 18F-FDG, 18F-FDG PET/CT
- Where
- India
- Volunteers
- 31 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective…
- Trial name
- NCT06588517
- Testing
- Pirfenidone Modified-Release Tablets, Pirfenidone Tablets
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Chronic Beryllium Disease
Targeting Oxidative Stress in Chronic Beryllium Disease
The purpose of this study is to understand if a drug called mesalamine helps to control inflammation associated with chronic beryllium disease (CBD).
- Trial name
- NCT01088243
- Testing
- Mesalamine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Jewish Health
Scleroderma, Systemic
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality.
- Trial name
- NCT02597933
- Testing
- Nintedanib
- Where
- 195 sites in United States, Argentina and 30 more
- Volunteers
- 580 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
- Trial name
- NCT00076635
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- InterMune
Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- OPTIMIZE-ILD-2 (NCT07486206)
- Testing
- Standard ILD Follow-Up Pathway, Optimized One-Day ILD Follow-Up Circuit
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Hospital de Granollers
Idiopathic Pulmonary Fibrosis
Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease characterized by a progressive damage of lung structure and decline in lung function.This study intends to carry out an open, single-center…
- Trial name
- NCT02745184
- Testing
- Lung stem cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai East Hospital
Pulmonary Arterial Hypertension, Interstitial Lung Disease
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT00705133
- Testing
- Treprostinil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rajan Saggar
Humoral Rejection, Guillain-Barre Syndrome
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
Plasma exchange procedures remove procoagulant and anticoagulant factors. Every procedure increases the risk of bleeding and repeated procedures increase the risk of bleeding mostly because lower fibrinogen levels.
- Conditions
- Humoral Rejection, Guillain-Barre Syndrome, Miller Fisher Syndrome, CIDP
- Trial name
- NCT03801135
- Testing
- Fibrinogen concentrate, Fresh Frozen Plasma
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- University Medical Centre Ljubljana
ILD
Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Ild
The main purpose of this study is to evaluate the effects of high-flow nasal therapy (HFNT) oxygen compared to long-term oxygen therapy (LTOT) on dyspnea and quality of life in intersititial lung disease patients with chronic…
- Trial name
- HIGHOXFILD (NCT06617078)
- Testing
- long-term oxygen therapy (LTOT), High Flow Nasal Therapy (HFNT)
- Volunteers
- 42 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris